The 2009 list of the top 20 pharmaceutical companies, ranked by IMS Health according to global prescription drug sales for the 12 months up to September 2009, shows that Teva, Novo Nordisk and Boehringer Ingelheim scored better in percent change than Big Pharma in those months.
IMS Health Top 20 pharmaceutical companies 2009
Home/Pharma News
|
Posted 23/04/2010
0
Post your comment
The data below does not take into account the large acquisitions by Pfizer and Merck, of Wyeth and Schering-Plough respectively, which were completed after September 2009.
| Company Sales | (billion US$) | % change |
| 1. Pfizer | 41.7 | (0.8) |
| 2. Novartis | 36.7 | 7.0 |
| 3. Sanofi-aventis | 35.1 | 3.3 |
| 4. GlaxoSmithKline | 34.3 | (3.4) |
| 5. AstraZeneca | 33.2 | 7.8 |
| 6. Roche | 31.3 | 8.6 |
| 7. Johnson & Johnson | 26.9 | (6.6) |
| 8. Merck & Co | 25.0 | (4.1) |
| 9. Eli Lilly | 19.6 | 8.3 |
| 10. Abbott | 19.4 | 5.5 |
| 11. Teva | 15.7 | 12.3 |
| 12. Bayer | 15.4 | 3.9 |
| 13. Wyeth | 14.8 | (2.3) |
| 14. Amgen | 14.8 | (3.1) |
| 15. Boehringer Ingelheim | 14.6 | 10.4 |
| 16. Takeda | 14.4 | 2.1 |
| 17. Bristol-Myers | 14.2 | 5.8 |
| 18. Schering-Plough | 13.1 | 4..3 |
| 19. Daiichi Sankyo | 8.5 | 3.1 |
| 20. Novo Nordisk | 8.2 | 11.6 |
References:
IMS Health
FACTBOX-The 20 largest pharmaceutical companies. Reuters. 2010 March 26.
Guidelines
Brazil's ANVISA updates guidance on pharmacokinetic studies for biosimilars
Canada eliminates phase III trial requirement for biosimilar approvals
Policies & Legislation
ANVISA and DINAVISA sign MoU to strengthen border surveillance and regulatory cooperation
Congress pushes biosimilar bills as interchangeability concerns linger
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Biosimilar race: Sandoz expands pipeline with Henlius, Teva secures ocrelizumab candidate
Sun Pharma completes $11.75bn financing syndication for Organon acquisition
Sun Pharma's Organon deal set to reshape biosimilars competitive landscape
Amgen expansion, BioNTech retrenchment highlight diverging manufacturing strategies in biopharma
Related content
Biosimilar race: Sandoz expands pipeline with Henlius, Teva secures ocrelizumab candidate
Home/Pharma News Posted 02/09/2026
Sun Pharma completes $11.75bn financing syndication for Organon acquisition
Home/Pharma News Posted 20/08/2026
Sun Pharma's Organon deal set to reshape biosimilars competitive landscape
Home/Pharma News Posted 12/06/2026
Amgen expansion, BioNTech retrenchment highlight diverging manufacturing strategies in biopharma
Home/Pharma News Posted 05/06/2026
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment